ArticleDiscover oncology2025
The role of immune cells phenotype in neuroendocrine tumors development.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeuroendocrine tumors (NETs) are closely linked to immune disorders, yet the causal relationship between them remains incompletely explored. This study investigates the causal associations between 731 immune features and six types of NETs.
methodA bidirectional, two-sample Mendelian randomization (MR) analysis is employed to examine the causal relationship between immune cell characteristics and NETs. Publicly available genome-wide association study (GWAS) genetic data are analyzed to explore causal links between 731 immune cell phenotypes and the risk of six NETs.
resultsAfter false discovery rate (FDR) correction, no statistically significant effect of the six NETs on the immunophenotype is observed. However, T cells play a crucial role in the development of gastric neuroendocrine tumors (GNETs). Specifically, SSC-A on CD4+ T cells significantly reduces the likelihood of developing GNETs, with an odds ratio (OR) of 0.16 (95% CI=0.084-0.328, P = 2.58×10⁻⁷, FDR = 1.16×10⁻⁴). Terminally differentiated CD4⁻CD8⁻ T cells (OR=14.37, 95% CI=3.647-56.587, P =1.39×10⁻⁴, FDR=0.021) and naive CD4+ T cells (OR=5.32, 95% CI=2.513-11.284, P =1.27×10⁻⁵, FDR=0.0029) are associated with an increased risk of GNETs.
conclusionsThis study elucidates the causal relationship between 731 immune cells and six types of NETs, identifying three immune phenotypes significantly associated with GNETs pathogenesis. These findings provide new perspectives for future medical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.